Physiomics models for Lilly

Physiomics has signed an agreement with Eli Lilly and Company to provide computer simulations of cancer cellular processes


Oxford-based systems biology company Physiomics has signed an agreement with pharmaceutical giant Eli Lilly and Company to provide computer simulations of cancer cellular processes.


Physiomics biological systems computer modelling techniques, known as in silico simulation, will be used to support Lilly’s cancer drug discovery research. The company will work alongside Lilly’s global PK/PD/TS (pharmacokinetics, pharmacodynamics and trial simulation) department and oncology discovery group.


The research programme will initially focus on drugs aimed at restoring the cell cycle – the natural process of controlling cell proliferation – which is frequently disrupted in cancers.


Dr Christophe Chassagnole, chief operating officer of Physiomics, said: ‘This is a very positive step forward for Physiomics as a further major pharmaceutical company joins our growing list of partners at a time when interest in application of systems biology to pharmaceutical R&D is increasing very rapidly.’


Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The company has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes, including multi-cellular environment software which enables the simulation of a population of ‘virtual cells’.